Modifying T cells with CARs or αβ T-cell receptors (TCRs) is an attractive strategy to readily generate tumor-specific T cells ex vivo28, 29, and early phase clinical studies have shown impressive clinical responses especially for CD19-positive hematological malignancies. This evidence concerns the gene CD19 and neoplasm.